COR Stock Analysis: Cencora | NYSE
Medical Distribution | NYSE, USA | Market Cap: 59.905m USD | 12M Return: 4.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 484M
EPS Trend: 99.8%
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cencora, Inc. (NYSE: COR) is a large-cap U.S. pharmaceutical distributor operating through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The company sources and distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies, plasma and blood products, vaccines, specialty drugs, and animal health products. Its customer base spans acute care hospitals, health systems, retail and mail-order pharmacies, medical clinics, long-term care facilities, and veterinary markets.
Beyond physical distribution, Cencora offers a broad services portfolio, including pharmacy management and consulting, supply management software, packaging solutions, clinical trial and commercialization support, data analytics, sales force services for manufacturers, and specialty transportation and logistics for the biopharmaceutical industry. The company was founded in 1871, is headquartered in Conshohocken, Pennsylvania, and was renamed from AmerisourceBergen Corporation to Cencora, Inc. in August 2023.
As a member of the U.S. drug wholesaling Big 3 alongside McKesson and Cardinal Health, Cencora operates in a high-volume, low-margin industry that serves as a critical link between pharmaceutical manufacturers and a fragmented base of healthcare providers, giving it significant scale advantages in purchasing and logistics.
- GLP-1 drug volumes accelerate U.S. pharmaceutical distribution growth
- Opioid litigation settlements pressure near-term operating margins
- Specialty pharma services revenue scales double digits globally
| Net Income: 2.55b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.11 > 1.0 |
| NWC/Revenue: -0.91% < 20% (prev -2.19%; Δ 1.28% < -1%) |
| CFO/TA 0.03 > 3% & CFO 2.28b > Net Income 2.55b |
| Net Debt (10.1b) to EBITDA (5.00b): 2.03 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.4m) vs 12m ago 0.15% < -2% |
| Gross Margin: 3.47% > 18% (prev 2.94%; Δ 0.52% > 0.5%) |
| Asset Turnover: 430.1% > 50% (prev 435.8%; Δ -5.68% > 0%) |
| Interest Coverage Ratio: 8.35 > 6 (EBIT TTM 3.96b / Interest Expense TTM 474.0m) |
| A: -0.04 (Total Current Assets 53.1b - Total Current Liabilities 56.1b) / Total Assets 81.7b |
| B: 0.10 (Retained Earnings 8.49b / Total Assets 81.7b) |
| C: 0.05 (EBIT TTM 3.96b / Avg Total Assets 76.4b) |
| D: 0.04 (Book Value of Equity 3.40b / Total Liabilities 78.1b) |
| Altman-Z'' = 0.49 = B |
| DSRI: 0.99 (Receivables 24.9b/23.7b, Revenue 329b/310b) |
| GMI: 0.85 (GM 2.94% / 3.47%) |
| AQI: 1.00 (AQ_t 0.31 / AQ_t-1 0.31) |
| SGI: 1.06 (Revenue 329b / 310b) |
| TATA: 0.00 (NI 2.55b - CFO 2.28b) / TA 81.7b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of July 21, 2026, the stock is trading at USD 303.99 with a total of 902,924 shares traded. Over the past week, the price has changed by -0.70%, over one month by +12.06%, over three months by -5.67% and over the past year by +4.65%.
Current recommended Stop Loss: 292.20 (which is 3.9% or 1.5 ATR below the current price).
Cencora has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy COR.
- StrongBuy: 8
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 353.5 | 16.3% |
P/E Trailing = 23.5939
P/E Forward = 15.3846
P/S = 0.1823
P/B = 17.6317
P/EG = 0.6518
Revenue TTM = 329b USD
EBIT TTM = 3.96b USD
EBITDA TTM = 5.00b USD
Long Term Debt = 12.3b USD (from longTermDebt, last quarter)
Short Term Debt = 202.7m USD (from shortTermDebt, last quarter)
Debt = 12.4b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.1b USD (calculated: Debt 12.4b - CCE 2.24b)
Enterprise Value = 70.1b USD (59.9b + Debt 12.4b - CCE 2.24b)
Interest Coverage Ratio = 8.35 (Ebit TTM 3.96b / Interest Expense TTM 474.0m)
EV/FCF = 44.96x (Enterprise Value 70.1b / FCF TTM 1.56b)
FCF Yield = 2.22% (FCF TTM 1.56b / Enterprise Value 70.1b)
FCF Margin = 0.47% (FCF TTM 1.56b / Revenue TTM 329b)
Net Margin = 0.78% (Net Income TTM 2.55b / Revenue TTM 329b)
Gross Margin = 3.47% ((Revenue TTM 329b - Cost of Revenue TTM 317b) / Revenue TTM)
Gross Margin QoQ = 4.24% (prev 3.27%)
Tobins Q-Ratio = 0.86 (Enterprise Value 70.1b / Total Assets 81.7b)
Interest Expense / Debt = 3.83% (Interest Expense 474.0m / Debt 12.4b)
Taxrate = 27.21% (954.1m / 3.51b)
NOPAT = 2.88b (EBIT 3.96b * (1 - 27.21%))
Current Ratio = 0.95 (Total Current Assets 53.1b / Total Current Liabilities 56.1b)
Debt / Equity = 3.65 (Debt 12.4b / totalStockholderEquity, last quarter 3.40b)
Debt / EBITDA = 2.03 (Net Debt 10.1b / EBITDA 5.00b)
Debt / FCF = 6.51 (Net Debt 10.1b / FCF TTM 1.56b)
Total Stockholder Equity = 2.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.33% (Net Income 2.55b / Total Assets 81.7b)
RoE = 115.9% (Net Income TTM 2.55b / Total Stockholder Equity 2.20b)
RoCE = 27.39% (EBIT 3.96b / Capital Employed (Equity 2.20b + L.T.Debt 12.3b))
RoIC = 12.27% (NOPAT 2.88b / Invested Capital 23.5b)
WACC = 4.62% (E(59.9b)/V(72.3b) * Re(5.0%) + D(12.4b)/V(72.3b) * Rd(3.83%) * (1-Tc(0.27)))
Discount Rate = 5.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.72 | Cagr: -1.43%
[DCF] Terminal Value 73.10% ; FCFF base≈2.36b ; Y1≈2.07b ; Y5≈1.68b
[DCF] Fair Price = 86.08 (EV 26.9b - Net Debt 10.1b = Equity 16.7b / Shares 194.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 99.78 | EPS CAGR: 14.43% | SUE: 0.22 | # QB: 0
Revenue Correlation: 99.03 | Revenue CAGR: 10.17% | SUE: -2.19 | # QB: -1
EPS current Quarter (2026-06-30): EPS=4.35 | Chg30d=-0.09% | Revisions=+0% | Analysts=12
EPS current Year (2026-09-30): EPS=17.78 | Chg30d=+0.09% | Revisions=+25% | GrowthEPS=+11.1% | GrowthRev=+4.9%
EPS next Year (2027-09-30): EPS=19.82 | Chg30d=+0.17% | Revisions=+50% | GrowthEPS=+11.5% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +31% (up=7, down=3)